Endologix (ELGX) 8-K Will Expand U.S. and European Sales Organizations to Enhance Growth and Provide Excellent Clinical Support

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statement on Form S-3 (Nos. 333-181762, 333-171639, 333-159078, 333-133598, 333-107286, 333-35343, 333-33997, 333-71053, 333-52474, 333-90960, 333-126710, and 333-114140) and S-8 (Nos. 333-206208, 333-190393, 333-187258, 333-168465, 333-160317, 333-152774, 333-136370, 333-122491, 333-114465, 333-52482, 333-72531, 333-59305, 333-42161, and 333-07959) of Endologix, Inc. of our report dated March 9, 2015 relating to the financial statements of TriVascular Technologies, Inc., which appears in this Current Report on Form 8-K of Endologix, Inc.

/s/ PricewaterhouseCoopers LLP

San Jose, California

October 26, 2015